Physician

Kanwaljit S. Mahal, M.D.

According to 2025 Medicare claims, Kanwaljit Mahal, M.D. (NPI: 1447361092) practices urology in the Lubbock, TX market, with the plurality of this provider's patient population coming from Lubbock, TX. This provider's primary affiliated billing organization is LUBBOCK UROLOGY CLINIC, LLP (NPI: 1629012844; TIN: 751514281) and primary practice location at 79424-0803. Mahal is affiliated with the Caravan Health ACO 43 LLC (ACO ID: A4974), Main Street Rural Health Sycamore ACO LLC (ACO ID: A5403), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Mahal's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 632 traditional Medicare patients, billed 9,453 HCPCS/CPT codes, and received $297,284 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,282 prescription claims across 502 beneficiaries totaling $481,478 in drug costs, led by Xtandi (Enzalutamide). DME data shows 33 claims. Open Payments data shows 41 records totaling $2,199. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $268,207 and ending at $481,478. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $514 and ending at $247.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	716	5,785	$217,919
2016	753	6,864	$223,671
2017	755	9,663	$292,948
2018	737	9,514	$276,743
2019	701	10,798	$264,792
2020	659	8,286	$202,159
2021	664	9,462	$248,228
2022	653	8,940	$224,650
2023	682	10,389	$300,390
2024	632	9,453	$297,284

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	349	1,679	$268,207
2016	376	1,731	$412,427
2017	388	1,945	$456,402
2018	459	2,146	$785,931
2019	441	1,973	$681,731
2020	403	1,928	$491,457
2021	433	1,870	$383,857
2022	456	2,054	$355,945
2023	481	2,014	$480,354
2024	502	2,282	$481,478

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	29	$4,128
2016	N/R	114	$10,948
2017	N/R	65	$20,314
2018	N/R	11	$2,447
2019	N/R	47	$3,759
2020	N/R	45	$6,045
2021	N/R	33	$6,651
2022	N/R	36	$8,829
2023	N/R	43	$11,848
2024	N/R	33	$11,356

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	330	508	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	242	402	$57
84153	Psa (prostate specific antigen) measurement, total	303	452	$18
36415	Insertion of needle into vein for collection of blood sample	349	536	$9
81003	Automated urinalysis test	475	934	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	11	330	$153,106
Myrbetriq	Mirabegron	157	7,288	$107,795
Gemtesa	Vibegron	66	2,520	$38,364
Mirabegron Er	Mirabegron	34	2,160	$21,033
Tamsulosin Hcl	Tamsulosin Hcl	748	51,529	$8,176

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4351	Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each	N	N/R	33	$11,356

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	41	$2,199	PROCEPT BioRobotics Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kanwaljit S. Mahal, M.D.?

Tedicare shows public-source Medicare data for Kanwaljit S. Mahal, M.D. (NPI 1447361092), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kanwaljit S. Mahal, M.D. have ACO affiliation data?

Kanwaljit S. Mahal, M.D. is shown with ACO affiliation data for Caravan Health ACO 43 LLC (MSSP, ACO ID A4974), Main Street Rural Health Sycamore ACO LLC (MSSP, ACO ID A5403), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Kanwaljit S. Mahal, M.D.?

Kanwaljit S. Mahal, M.D. is linked to LUBBOCK UROLOGY CLINIC, LLP (billing NPI 1629012844) in the available physician profile data.

Does Kanwaljit S. Mahal, M.D. have Open Payments data?

Kanwaljit S. Mahal, M.D. has 41 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.